The Rare Disease Economics and Orphan Drug Commercialization Summit 2014 covers topics such as:
- Impending economic evolution in the rare disease landscape
- Methods to increase orphan drug speed to market at a lower price to the patient
- Strategies for pricing and cost saving valuation of orphan drugs
- Factors affecting reimbursement and formulary decisions
- Issues from a Tufts Center for the Study of Drug Development Impact Report
- Findings on global orphan drug patient
The Rare Disease Economics and Orphan Drug Commercialization Summit 2014 brings together senior attendees from:
- Market access and commercialization from biotech and pharmaceutical companies within divisions of genetic, rare and orphan diseases
- Pricing
- Regulatory
- Reimbursement
- Health Economics
- Marketing
- Policy
- Outcomes Research
- Medical Directors
- P&T Committees
- Orphan Foundations/Associations
- Business Development
- Contract Research Organizations
- Product launch
- Advocacy Groups
- Medical and Pharmacy Payers
- Academia
